Smartphone App Detects Eye Cancers From Photos

Published Date: 09 Jun 2026

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Read Full News

Latest News

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Todays Updates

Rare Adenoid Cystic Breast Cancer in a Woman

A woman with rare breast adenoid cystic carcinoma carries a BRIP1 variant of uncertain significance, highlighting the challenges in genetic risk assessment.

What the FDA's Hormone Therapy Decision Means for Aging Skin

Skin collagen content decreases at a rate of approximately 1%-2% per year in the early postmenopausal period, skin thickness diminishes, barrier function weakens, and moisture retention falters

J&J Beats Lawsuit Alleging That Talc Caused Three Women's Cancer

A Los Angeles jury on Friday sided with ⁠Johnson & Johnson in a lawsuit by the families of three women who alleged ⁠that the company's talc products caused ovarian...

Extended-Release Febuxostat Beats Standard Drug for Gout

A new 24-hour version of febuxostat lowers uric acid levels significantly better than the standard drug for patients with severe gout, though it may carry a higher risk of serious side effects.

Why Are Ketogenic Diets Effective for Epilepsy?

A century-old dietary therapy remains one of neurology’s most effective treatments for drug-resistant epilepsy — and one of its least understood.

Maternal RSV Vaccine Cuts Infant Hospitalization Risk by 68%

Maternal RSV vaccination during pregnancy is associated with protection against RSV-associated acute respiratory illness.

Berlin Hospital Discharges US Doctor Who Contracted Ebola

A U.S. citizen treated in Germany ⁠after contracting Ebola in the Democratic Republic of Congo has been discharged, ⁠a Berlin hospital said on Saturday.

Todays Updates

Rare Adenoid Cystic Breast Cancer in a Woman

A woman with rare breast adenoid cystic carcinoma carries a BRIP1 variant of uncertain significance, highlighting the challenges in genetic risk assessment.

What the FDA's Hormone Therapy Decision Means for Aging Skin

Skin collagen content decreases at a rate of approximately 1%-2% per year in the early postmenopausal period, skin thickness diminishes, barrier function weakens, and moisture retention falters

J&J Beats Lawsuit Alleging That Talc Caused Three Women's Cancer

A Los Angeles jury on Friday sided with ⁠Johnson & Johnson in a lawsuit by the families of three women who alleged ⁠that the company's talc products caused ovarian...

Extended-Release Febuxostat Beats Standard Drug for Gout

A new 24-hour version of febuxostat lowers uric acid levels significantly better than the standard drug for patients with severe gout, though it may carry a higher risk of serious side effects.

Why Are Ketogenic Diets Effective for Epilepsy?

A century-old dietary therapy remains one of neurology’s most effective treatments for drug-resistant epilepsy — and one of its least understood.

Maternal RSV Vaccine Cuts Infant Hospitalization Risk by 68%

Maternal RSV vaccination during pregnancy is associated with protection against RSV-associated acute respiratory illness.

Berlin Hospital Discharges US Doctor Who Contracted Ebola

A U.S. citizen treated in Germany ⁠after contracting Ebola in the Democratic Republic of Congo has been discharged, ⁠a Berlin hospital said on Saturday.

Latest News

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

News All Time

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Less Mental Decline With Darolutamide vs Enzalutamide in PC

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Researchers are testing CAR T-cell therapy as a way to reset the immune system in lupus, Graves’ disease and other conditions where the body’s defenses go rogue.

France Expands 2026 Vaccination Rules Amid Resurgence

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

Antibiotic Stewardship: Five Tips to Reduce Resistance

Clinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

All-Oral Treatment Combo for AML Earns FDA Nod

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

Recommended News For You

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.

WHO launches plan for free child cancer medicines

The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.

Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer

Sickle Cell Disease Drug Pulled From Global Markets

Morning Immunotherapy Does Not Boost Lung Cancer Survival

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

Recommended Articles For You

Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms 

Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength 

The Cutting-Edge of Phlebectomy: Redefining Vein Care 

Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The most precise research tools for the deadliest blood cancer have been developed.

2.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

3.

What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains

4.

Brain cancer: a Q&A session.

5.

An ancient signaling pathway and 20 years of research offer hope for rare cancer

1.

Benefits of Neutrophilia: Harnessing the Power of White Blood Cells to Promote Health and Well-Being

2.

Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care

3.

ERASur: Evaluating Total Ablative Therapy in Limited Metastatic Colorectal Cancer

4.

RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health 

5.

All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

International Lung Cancer Congress®

3.

Genito-Urinary Oncology Summit 2026

4.

Future NRG Oncology Meeting

5.

ISMB 2026 (Intelligent Systems for Molecular Biology)

1.

Navigating the Complexities of Ph Negative ALL - Part XVI

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI

3.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

4.

Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot